INTRODUCTION
Since the introduction of combination antiretroviral therapy (ART), significant improvement in mortality has been observed in HIV-infected individuals. However, serious non-AIDS events, including cardiovascular disease, malignancy, bone disorders, and neurocognitive impairment account for most morbidity and mortality in the ART-treated population [1, 2] . ART side-effects were hypothesized to drive these events, but the Strategies for Management of Antiretroviral Therapy (SMART) study showed that people not receiving continuous ART had a higher frequency of non-AIDS events [3] . Some studies have now affirmed the association of HIV infection with non-AIDS events. Measurements of soluble biomarkers in SMART and subsequent studies have further highlighted that inflammation is an independent predictor of all-cause mortality, cardiovascular events, and other morbidities in chronic, treated HIV infection [4,5,6 & ]. Indeed, systemic inflammation has been recognized as a seminal feature of HIV infection. Whether ART alone could normalize the inflammatory state if started early, namely during acute infection or at CD4 T-cell counts even higher than 500 cells/mm 3 , remains unclear as most available data are derived from people starting ART in chronic infection with CD4 T-cell counts frequently below current WHO treatment guidelines (http://www. who.int/hiv/pub/guidelines/arv2013/intro/rag/en/ index2.html). Randomized controlled studies of conventional treatment strategies compared with early ART that correlate biomarkers of inflammation and coagulation with clinical events will address this question.
The terms inflammation and immune activation have been used interchangeably in HIV literature, but they reflect different processes. 'Inflammation' refers to the production of cytokines and other mediators primarily by macrophages in response to a stimulus, resulting in rubor, dolor, calor, and tumor (redness, pain, heat, and swelling) and subsequently immune cell recruitment and release of more inflammatory mediators [7] . 'Immune activation,' in turn, describes cellular activation indicated by the expression of markers on lymphocytes, monocytes, or antigen presenting cells. T-cell activation is often characterized by HLA-DR and/or CD38 expression, Ki67 expression to indicate cycling, and BrdU incorporation and decay to reflect cell turnover [8] . However, numerous other markers of cellular activation exist including molecules that also regulate immune responses (such as PD-1) [9] . Thus, we prefer 'immune activation' to describe increases in cellular markers of activation and 'inflammation' to describe the systemic response detected by increases in soluble biomarkers of inflammation.
Many inflammatory biomarkers such as IFNa, TNF, and IL-6, reflecting innate immune system activation, increase during acute HIV infection, coincide with peak viremia, and decrease but remain elevated into chronic infection [10,11 && ]. In acute infection, high IFNg-induced protein 10 (IP-10) levels predicted disease progression, defined as CD4 T-cell loss [11 && ], and monocyte activation markers such as neopterin were recognized decades ago as independent predictors of chronic HIV disease progression [12] . Type I interferons (IFN-Is), which stimulate antiviral gene expression, are also thought to drive disease progression based on nonhuman primate studies demonstrating their persistent elevation in progressive but not nonprogressive simian immunodeficiency virus (SIV) infection [13, 14] . However, blocking IFN-I signaling in rhesus macaques during acute SIV infection resulted in accelerated disease progression, reflecting the importance of early viral control in disease outcomes [15] . In chronic-treated HIV infection, elevated levels of soluble markers of inflammation and coagulation, including IL-6, D-dimer, high-sensitivity C-reactive protein (hsCRP), soluble CD14 (sCD14), and soluble CD163 (sCD163), were shown to predict cardiovascular events, progression to AIDS, and all-cause mortality [4,5,6 & , [16] [17] [18] . CD4 and CD8 T-cell activation also increase during acute infection, correlate with viremia, and remain elevated during chronic infection [19] [20] [21] . Increased CD8 T-cell activation was recognized early as an independent predictor of disease progression [22] , even when measured before seroconversion [23] . Greater CD8 T-cell activation predicted a faster rate of CD4 T-cell decline without ART [20] 
Effect of antiretroviral therapy on inflammation and T-cell activation
ART dramatically decreases most markers of immune activation and inflammation in peripheral blood and tissue [16, 17, [42] [43] [44] It is possible, yet presently unclear, that early ART may substantially decrease or eliminate residual inflammation in chronic-treated infection by diminishing residual virus and preserving a more intact T-cell pool.
replication, gut mucosal injury and subsequent microbial translocation, tissue fibrosis, coinfections such as cytomegalovirus (CMV) and hepatitis C virus, and homeostatic drive [46, 47] . The contribution of each of these factors may vary depending when ART is initiated (acute or chronic infection, high or low CD4 T-cell counts), degree of CD4 T-cell restoration, age, comorbidities, and genetic background [48] .
Biomarkers that associate independently with morbidity and mortality in patients on ART reflect predominantly chronic activation of the innate rather than adaptive immune system. Two recent studies demonstrated that only soluble markers of inflammation, not T-cell activation, independently predict clinical events [49, 50] . A hyperactive innate immune system is more proximal to the vascular and endothelial complications of HIV, but the adaptive system may still contribute. CD8 T cells from HIV-infected individuals express increased proteaseactivated receptor (PAR)-1, which increases thrombin-enhanced IFNg secretion, and thereby links vascular injury and coagulation with the adaptive T-cell response [51 && ]. As immunologic response clearly depends on age at ART initiation and nadir CD4 cell count, it is feasible that earlier ART at higher CD4 cell counts (and consequently also at younger age) could lead to more robust CD4 T-cell restoration and lower morbidity and mortality. Indeed, individuals that initiated ART less than 4 months postinfection with CD4 T-cell counts greater than 500 cells/ml were more likely to attain CD4 T-cell counts greater than 800 cells/ml than those that started later [ 
Antiretroviral therapy intensification and differential effects of antiretroviral drugs on inflammation and immune activation

CD38
þ CD8 T cells decreased to a greater extent and cell-associated HIV DNA and RNA were lower in individuals starting ART within 6 months of infection compared with those starting at least 2 years postinfection [82 && ]. Higher CD8 T-cell activation was associated with higher cumulative viremia and lower pre-ART CD4 T-cell count in the delayed ART group. Together, these studies suggest that early ART results in less cell-associated virus, less cumulative viremia, and subsequently lower CD8 T-cell activation during chronic HIV infection.
The effects of early ART on biomarkers of inflammation are heterogeneous. Levels of IFNa, D-dimer, and IP-10 but not sCD14, decreased whereas CD4 T-cell counts increased with ART initiated during acute HIV infection [83 & ]. This decrease in inflammatory markers was accompanied by a decrease in cell-associated HIV DNA. Similarly, ART initiated within 1 year of infection normalized levels of sCD163, a monocyte activation marker correlated with noncalcified arterial plaque and neurocognitive impairment, but not if initiated later [17, 84, 85 & ]. In contrast, sCD14 levels increased in the early ART group whereas remaining unchanged in the later group [17] , suggesting that early ART may not affect all inflammatory pathways similarly.
Even transient early ART can decrease T-cell activation in chronic infection. In the ViroImmunological Sustained Control after Treatment Interruption (VISCONTI) study, participants that took ART for 3 years starting 1.6 months postinfection had, after discontinuation, lower levels of cellassociated HIV DNA and comparable CD8 T-cell activation with those still taking ART during chronic infection and maintained virologic suppression and steady CD4 T-cell counts for over 7 years [86 && ]. In a similar study, 14 individuals that received 1-2 years of ART initiated within 3 months of infection maintained virologic suppression for about 4.5 years and steady CD4 T-cell counts for up to 8 years [87 & ]. These participants had higher CD4 T-cell counts at baseline and at ART interruption and lower CD38 þ CD8 T-cell frequencies than the 136 post-ART noncontrollers. Together, these studies identify a population of posttreatment controllers that maintain small HIV reservoirs, low CD8 T-cell activation, and high CD4 T-cell counts, reflecting the association of viral replication, T-cell activation, and CD4 depletion.
In sum, initiating ART during the first year of HIV infection results in reduced T-cell activation and numerous biomarkers of inflammation, predictors of progression to AIDS [12, 17, 20, 23, 25 & ], cardiovascular disease [84, 88] , and mortality [27] . However, whether initiating ART during acute HIV infection is more beneficial on inflammation and immune activation, potentially because of an early effect on the viral reservoir, than starting ART during chronic HIV infection with a high CD4 T-cell count is unknown. In addition, although decreasing viral replication may decrease inflammation, as noted above, long-term exposure to some antiretroviral drugs may contribute to hyperlipidemia, inflammation, and potentially end-organ disease. Furthermore, the optimal way to quantify viral replication and the viral reservoir is unclear, and these viral measurements have not been directly correlated with the biomarkers of interest (D-dimer, sCD14, IL-6, hsCRP, sCD163, etc.) or validated as independent clinical predictors through the robustness of a large database.
It is possible that early ART will not completely eliminate inflammation, and it may not be feasible for all patients. Other modalities that target inflammation directly may be necessary to improve clinical outcomes. Studies of aspirin, statins, and methotrexate, among others, in HIV-uninfected individuals have demonstrated a decrease in inflammatory biomarkers such as IL-6, hsCRP, and D-dimer, and subsequently a reduction in cardiovascular events [89] [90] [91] [92] [93] .
Recent studies of agents to decrease immune activation and inflammation in HIV-infected individuals have been modestly successful. Prebiotic oligosaccharide administration to HIV-infected individuals not taking ART decreased plasma sCD14 levels [94] , and both celecoxib [95] and valganciclovir targeting CMV coinfection [96] decreased CD8 T-cell activation. The optimal approach may be to target either multiple drivers of inflammation simultaneously, that is, residual viral replication, microbial translocation, and coinfections, or the final common pathway, that is, possibly monocyte activation or the intersection of the inflammation and coagulation pathways. Numerous ongoing studies aim to decrease inflammation in HIV-infected individuals using aspirin, statins, rifaximin, sevelamer, angiotensinreceptor blockers, methotrexate, and other agents [47, [97] [98] [99] . The results of these studies will provide a better understanding of both the inflammatory pathways with their related biomarkers and their role in end-organ disease in HIV-infected individuals.
CONCLUSION
Early ART in chronic infection would clearly benefit certain HIV-infected persons (with hepatitis B or C coinfection, high cardiovascular risk, risk for tuberculosis acquisition, older age), and accumulating evidence suggests that early ART could attenuate at least some aspects of the chronic inflammatory state of treated HIV infection. Whether this reduction in inflammation would result in fewer non-AIDS events, as data from studies from the HIV-uninfected population suggest, remains unclear. The link of biomarkers or their modification with clinical events may be further unraveled in new clinical endpoint studies such as Strategic Timing of Anti-Retroviral Treatment (START) and Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO) that will help support or disprove the hypothesis. Despite the controversy of how early to start, the frustrating reality is that throughout the past decade, the average CD4 cell count at diagnosis has remained below 350 cells/ml [100 & ]. Earlier diagnosis and treatment, at least in accordance with existing guidelines, represents the first and foremost attainable task in the near future.
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